Mupadolimab

莫帕利单抗

Report date: 2024/01/10 16:46:12

Base Information

Drug NameMupadolimab
Drug Alias NameAnti-CD73 MAb (Corvus)Adenosine production inhibitor (Corvus Pharmaceuticals)CPI-006CPX-006COR-004 (Corvus Pharmaceuticals)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-5'-nucleotidaseAdenosine production inhibitors
Targets5'-nucleotidase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursUrinary Bladder Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCorvus Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAngel Pharmaceuticals Co LtdCorvus Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A